“Hemorrhage is a well-known complication of essential thrombocythemia (ET) and polycythemia vera (PV), but evidence-based data on its management and prevention are lacking to help inform clinicians”

“Myeloproliferative neoplasms (MPNs) are a group of hematological malignancies individualized in the 2016 World Health Organization (WHO) classification.1 They are subdivided into two groups: chronic myeloid leukemia and Philadelphia-negative MPNs, which are further divided into essential thrombocythemia (ET), polycythemia vera (PV), primitive myelofibrosis (PMF), and prefibrotic myelofibrosis.Philadelphia-negative MPNs are characterized by the chronic proliferation of myeloid cells in bone marrow and three main clonal mutations.”